Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non ...
MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE)-- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...
Investing.com - Mizuho initiated coverage on Eikon Therapeutics Inc. (NASDAQ:EIKN) with an outperform rating and set a price target of $26.00. The target represents nearly 90% upside from the current ...
Investing.com - Morgan Stanley initiated coverage on Eikon Therapeutics Inc. (NASDAQ:EIKN) with an overweight rating and a price target of $32.00, analyst Sean Laaman said Monday. The target ...
Eikon Therapeutics, Inc. (Nasdaq: EIKN), a California-based, late-stage biotechnology company, visits the Nasdaq MarketSite in Times Square. Eikon is led by executive and clinical teams behind the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...
Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...
Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...
Shares of Eikon Therapeutics are set to begin trading Thursday after the clinical-stage biopharmaceutical company's upsized initial public offering was priced at the top of expectations. Eikon late ...
Eikon Therapeutics raised an upsized US$381m late Wednesday from its Nasdaq IPO that included participation by Merck, a banker involved in the offering told IFR. The banks were multiple times ...
MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to ...
These are the ceremonies for February 2026. Market opening and closing ceremonies take place on weekdays at the Nasdaq MarketSite Studio in Times Square and around the globe. Eikon Therapeutics, Inc. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results